Duker J S, Brown G C
Retina Vascular Unit, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA.
Ophthalmology. 1989 Jan;96(1):92-5. doi: 10.1016/s0161-6420(89)32946-0.
Panretinal photocoagulation (PRP) is widely used for a variety of ischemic ocular conditions. In diseases that produce neovascularization of the iris (NVI), such as diabetes mellitus and central retinal vein obstruction, a judiciously timed PRP can reduce the incidence of neovascular glaucoma. Neovascularization of the iris can occur after central retinal artery obstruction (CRAO) as well. In this article, the authors report the outcome of 17 patients who received PRP to treat rubeosis iridis secondary to CRAO. Eleven of the 17 patients (65%) showed regression of NVI after PRP. Although the uncontrolled and retrospective nature of this study precludes drawing definitive conclusions from these data, PRP appears to be effective in reducing the incidence of neovascular glaucoma, if it is delivered before the development of elevated intraocular pressure (IOP). Once neovascular glaucoma occurs, additional modalities appear to be necessary in order to adequately control the elevated IOP.
全视网膜光凝（PRP）广泛应用于多种缺血性眼部疾病。在诸如糖尿病和视网膜中央静脉阻塞等可导致虹膜新生血管形成（NVI）的疾病中，适时进行PRP可降低新生血管性青光眼的发生率。视网膜中央动脉阻塞（CRAO）后也可发生虹膜新生血管形成。在本文中，作者报告了17例接受PRP治疗继发于CRAO的虹膜红变患者的治疗结果。17例患者中有11例（65%）在PRP治疗后NVI消退。尽管本研究的非对照性和回顾性性质使得无法从这些数据得出明确结论，但如果在眼压（IOP）升高之前进行PRP，似乎对降低新生血管性青光眼的发生率有效。一旦发生新生血管性青光眼，似乎需要采用其他方法来充分控制升高的眼压。
